CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-Label, Multicentre Phase 1B/2A Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32B) in Combination With Ipilimumab and Pembrolizumab in Participants With Unresectable or Metastatic Melanoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06784648
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:57.384139+00:00
Published At: 2025-11-19T00:00:00+00:00
Record Updated At: 2025-11-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Melanoma Metastatic", "Melanoma of Skin", "Melanoma BRAF V600E/K Mutated", "Melanoma Recurrent", "Melanoma Stage III or IV", "Melanoma", "Melanoma Negative for bRAF", "Melanoma Negative for nRAS", "Melanomas", "Uveal Melanoma, Metastatic"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-11-19"
protocolSection.identificationModule.nctId: "NCT06784648"
protocolSection.identificationModule.officialTitle: "An Open-Label, Multicentre Phase 1B/2A Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to Fc\u03b3RIIB (CD32B) in Combination With Ipilimumab and Pembrolizumab in Participants With Unresectable or Metastatic Melanoma"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.